M R Larson1, P R Duberstein, N L Talbot, C Caldwell, J A Moynihan. 1. Center for Psychoneuroimmunology Research, University of Rochester Medical Center, 300 Crittenden Boulevard, Rochester, NY 14642, USA. Mark_Larson@URMC.ROCHESTER.EDU
Abstract
OBJECTIVE: The present study evaluated the feasibility and potential immunological benefit of a presurgical intervention for breast cancer patients. METHODS:Forty-one newly diagnosed breast cancer patients were randomized into control (standard care) and intervention groups. In addition to standard care, intervention group members received a two-session psychosocial intervention. Blood was drawn at three timepoints: (1) at preintervention; (2) at postintervention/presurgery; and (3) at postsurgery. RESULTS: Examination of the immunological data revealed evidence of suppression of interferon-gamma (IFN-gamma) in the control group over time, but not in the intervention group. Secondary findings related to psychological assessment generally paralleled the IFN-gamma results. CONCLUSION: The relevance and applicability of these findings to future breast cancer intervention research is detailed.
RCT Entities:
OBJECTIVE: The present study evaluated the feasibility and potential immunological benefit of a presurgical intervention for breast cancerpatients. METHODS: Forty-one newly diagnosed breast cancerpatients were randomized into control (standard care) and intervention groups. In addition to standard care, intervention group members received a two-session psychosocial intervention. Blood was drawn at three timepoints: (1) at preintervention; (2) at postintervention/presurgery; and (3) at postsurgery. RESULTS: Examination of the immunological data revealed evidence of suppression of interferon-gamma (IFN-gamma) in the control group over time, but not in the intervention group. Secondary findings related to psychological assessment generally paralleled the IFN-gamma results. CONCLUSION: The relevance and applicability of these findings to future breast cancer intervention research is detailed.
Authors: John M Salsman; James E Pustejovsky; Stephen M Schueller; Rosalba Hernandez; Mark Berendsen; Laurie E Steffen McLouth; Judith T Moskowitz Journal: J Cancer Surviv Date: 2019-11-19 Impact factor: 4.442
Authors: Lemmy Schakel; Dieuwke S Veldhuijzen; Paige I Crompvoets; Jos A Bosch; Sheldon Cohen; Henriët van Middendorp; Simone A Joosten; Tom H M Ottenhoff; Leo G Visser; Andrea W M Evers Journal: Psychother Psychosom Date: 2019-08-06 Impact factor: 17.659
Authors: Barbara L Andersen; William B Farrar; Deanna M Golden-Kreutz; Ronald Glaser; Charles F Emery; Timothy R Crespin; Charles L Shapiro; William E Carson Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: Anava A Wren; Rebecca A Shelby; Mary Scott Soo; Zenzi Huysmans; Jennifer A Jarosz; Francis J Keefe Journal: Support Care Cancer Date: 2019-01-31 Impact factor: 3.603
Authors: Christina Lindemalm; Fariba Mozaffari; Aniruddha Choudhury; Helena Granstam-Björneklett; Mats Lekander; Bo Nilsson; Marja-Leena Ojutkangas; Anders Osterborg; Leif Bergkvist; Håkan Mellstedt Journal: Support Care Cancer Date: 2007-06-12 Impact factor: 3.603